RN

Rein Therapeutics Inc.

RNTX · Nasdaq

Rein Therapeutics Inc. (RNTX) is a Medical pharmaceuticals company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Rein Therapeutics Inc. in 2026. The next earnings report is expected on November 13, 2026.

Earnings calendar

Next earnings date

13 Nov 2026

In 84 days

EPS estimate

-0.09

Revenue estimate

0

Past earnings

14 Aug 2026
EPS actual
-0.10 (+41.2%)
estimate -0.17
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
15 May 2026
EPS actual
-0.49 (0.0%)
estimate -0.49
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
26 Mar 2026
EPS actual
-1.09 (0.0%)
estimate -1.09
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 Nov 2025
EPS actual
-0.21 (+12.5%)
estimate -0.24
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Rein Therapeutics Inc. beat consensus on EPS, posting a loss per share of $0.10 versus an expected loss of $0.17, while revenue met estimates at $0.00. In the prior quarter, both EPS and revenue were in line with expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Sector
Healthcare
Industry
Medical pharmaceuticals
Country
United States
Exchange
Nasdaq
CEO
James Brian Windsor
Employees
11
IPO date
29 Jun 2017
ISIN
US00887A2042
Website
reintx.com

Frequently asked questions

When does Rein Therapeutics Inc. (RNTX) next report earnings?

Rein Therapeutics Inc. (RNTX) is scheduled to report earnings on November 13, 2026.

What was Rein Therapeutics Inc.'s most recent earnings date?

Rein Therapeutics Inc. (RNTX) last reported earnings on August 14, 2026.

Where is Rein Therapeutics Inc. stock listed?

Rein Therapeutics Inc. (RNTX) is listed on Nasdaq.